Market Closed -
Nyse
04:00:02 2024-07-05 pm EDT
5-day change
1st Jan Change
1.45
USD
+1.40%
+0.69%
-20.77%
Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.
On August 2, 2023, Cyclo Therapeutics, Inc. closed the transaction.
Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024
Jun. 14
CI
Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.
Jun. 10
CI
Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
Mar. 13
CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment
Dec. 19
DJ
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.
Dec. 14
CI
Rafael Holdings, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023
Dec. 14
CI
North American Morning Briefing : Traders Eye -2-
Dec. 12
DJ
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.
23-10-30
CI
Rafael Holdings, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023
23-10-30
CI
Rafael Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2023
23-10-30
CI
Earnings Flash (RFL) RAFAEL HOLDINGS Reports Q4 Revenue $68,000
23-10-30
MT
Earnings Flash (RFL) RAFAEL HOLDINGS Reports Q4 EPS $0.06
23-10-30
MT
Rafael Holdings, Inc. Announces Resignation of Rachel Jonas as Director
23-10-26
CI
Rafael Holdings, Inc. Announces Resignation of Boris Pasche as Director
23-08-09
CI
Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.
23-08-01
CI
Rafael Holdings, Inc.'s Equity Buyback Plan Extended till July 1, 2024.
23-06-30
CI
Rafael Holdings, Inc.'s Equity Buyback announced on April 4, 2023, has expired.
23-06-15
CI
Tranche Update on Rafael Holdings, Inc.'s Equity Buyback Plan announced on April 4, 2023.
23-06-13
CI
Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023
23-06-13
CI
Cyclo Therapeutics Signs $5 Million Funding Deal with Rafael Holdings
23-06-05
MT
Cyclo Therapeutics, Inc. announced that it expects to receive $5 million in funding from Rafael Holdings, Inc.
23-05-31
CI
Cyclo Therapeutics, Inc. announced that it has received $2.1 million in funding from Rafael Holdings, Inc.
23-05-01
CI
Rafael Holdings, Inc. announces an Equity Buyback for $5 million worth of its shares.
23-04-04
CI
Rafael Holdings, Inc. authorizes a Buyback Plan.
23-04-03
CI
Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
23-03-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Companyâs real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1